The Emirates Medical Association of Nephrology and Transplantation Society Consensus Statements on Optimizing Clinical Management of IgA Nephropathy: The Urgent Need for a Paradigm Shift in the UAE
Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerular disease worldwide. IgAN leads to end stage kidney disease in up to 40% - 50% of all patients and is associated with increased mortality, leading to a clear need for increased awareness and early treatment of the disease. In the United Arab Emirates (UAE), the number of IgAN diagnoses has steadily risen over several decades, putting increased pressure on primary care physicians and nephrologists to find nationwide solutions to optimize its clinical management. In recognition of this growing need, the Emirates Medical Association Nephrology and Transplantation Society (EMAN-T) convened a panel of 12 experts with recognized seniority in IgAN clinical management, who identified challenges and opportunities for improving and standardizing national IgAN care pathways. A limitation was a lack of patient or payer representation on the consensus panel. This expert clinical consensus article provides 6 consensus position statements that together set out a vision for optimal IgAN clinical management in the UAE. The statements are intended to serve as a first step towards optimizing IgAN awareness, diagnosis, risk assessment, treatment and ongoing clinical management, with the ultimate goal of improving care pathways for IgAN across the UAE.
References
[1]
Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M.A., et al. (2023) Long-Term Outcomes in IgA Nephropathy. ClinicalJournaloftheAmericanSocietyofNephrology, 18, 727-738. https://doi.org/10.2215/cjn.0000000000000135
[2]
Rout, P. and Afzal, M. (2025) IgA Nephropathy (Berger Disease). StatPearls Publishing.
[3]
Willey, C.J., Coppo, R., Schaefer, F., Mizerska-Wasiak, M., Mathur, M. and Schultz, M.J. (2023) The Incidence and Prevalence of IgA Nephropathy in Europe. NephrologyDialysisTransplantation, 38, 2340-2349. https://doi.org/10.1093/ndt/gfad082
[4]
Lee, H., Kim, D.K., Oh, K., Joo, K.W., Kim, Y.S., Chae, D., et al. (2012) Mortality of IgA Nephropathy Patients: A Single Center Experience over 30 Years. PLOSONE, 7, e51225. https://doi.org/10.1371/journal.pone.0051225
[5]
Knoop, T., Vikse, B.E., Svarstad, E., Leh, S., Reis？ter, A.V. and Bj？rneklett, R. (2013) Mortality in Patients with IgA Nephropathy. AmericanJournalofKidneyDiseases, 62, 883-890. https://doi.org/10.1053/j.ajkd.2013.04.019
[6]
Hastings, M.C., Bursac, Z., Julian, B.A., Villa Baca, E., Featherston, J., Woodford, S.Y., et al. (2018) Life Expectancy for Patients from the Southeastern United States with IgA Nephropathy. KidneyInternationalReports, 3, 99-104. https://doi.org/10.1016/j.ekir.2017.08.008
[7]
Jarrick, S., Lundberg, S., Welander, A., Carrero, J., H？ijer, J., Bottai, M., et al. (2019) Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study. JournaloftheAmericanSocietyofNephrology, 30, 866-876. https://doi.org/10.1681/asn.2018101017
[8]
Hassler, J.R. (2020) IgA Nephropathy: A Brief Review. Seminars in Diagnostic Pathology, 37, 143-147. https://doi.org/10.1053/j.semdp.2020.03.001
[9]
Stamellou, E., Seikrit, C., Tang, S.C.W., Boor, P., Tesa？, V., Floege, J., et al. (2023) IgA Nephropathy. NatureReviewsDiseasePrimers, 9, Article No. 67. https://doi.org/10.1038/s41572-023-00476-9
[10]
Ghani, A.A., Al Waheeb, S., Al Homoud, E., Al Helal, B. and Hussain, N. (2011) Clinical and Histopathological Spectrum of IgA Nephropathy in Kuwait. AnnalsofSaudiMedicine, 31, 152-157. https://doi.org/10.4103/0256-4947.77491
[11]
Alwahaibi, N., Al-Khazimi, O. and Al-Riyami, M. (2022) Histopathological Spectrum of Glomerular Diseases in Oman: A Five-Year Study. SaudiJournalofKidneyDiseasesandTransplantation, 33, 425-431. https://doi.org/10.4103/1319-2442.385966
[12]
Arrayed, A.A., Shariff, S. and Maamari, M.M.A. (2007) Kidney Disease in Bahrain: A Biopsy-Based Epidemiological Study. TransplantationProceedings, 39, 875-878. https://doi.org/10.1016/j.transproceed.2007.03.079
[13]
Mitwalli, A.H. (2000) Glomerulonephritis in Saudi Arabia: A Review. Saudi Journal of Kidney Diseases and Transplantation, 11, 567-576.
[14]
Yahya, T.M., Pingle, A., Boobes, Y. and Pingle, S. (1998) Analysis of 490 Kidney Biopsies: Data from the United Arab Emirates Renal Diseases Registry. Journal of Nephrology, 11, 148-150.
[15]
Alhadari, A.K., Alalawi, F.J., Seddik, A.A., Zahra, K., Kumar, D., Yousif, H., et al. (2017) Pattern of Acute Glomerulonephritis in Adult Population in Dubai: A Single-Center Experience. SaudiJournalofKidneyDiseasesandTransplantation, 28, 571-578. https://doi.org/10.4103/1319-2442.206443
[16]
Al Shamsi, H., El Tahrawi, R., Hindawy, B., Khater, E. and Hassan, M. (2020) Multicenter Review of Glomerular Diseases in the Emirates of Abu Dhabi: Six Years’ Experience. SaudiJournalofKidneyDiseasesandTransplantation, 31, 1069-1077. https://doi.org/10.4103/1319-2442.301173
[17]
Rovin, B.H., Barratt, J., Cook, H.T., Noronha, I.L., Reich, H.N., Suzuki, Y., et al. (2025) KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). KidneyInternational, 108, S1-S71. https://doi.org/10.1016/j.kint.2025.04.004
[18]
Ramsawak, S., Cohen, S., Linares, A. and Cavanaugh, C. (2025) IgA Nephropathy: Update on Pathogenesis and Treatment. ClevelandClinicJournalofMedicine, 92, 373-383. https://doi.org/10.3949/ccjm.92a.24105
[19]
Aseem, S. and Zheng, S. (2024) Immunoglobulin A Nephropathy: A Review. ThePermanenteJournal, 28, 87-94. https://doi.org/10.7812/tpp/24.089
[20]
Wyatt, R.J. and Julian, B.A. (2013) IgA Nephropathy. NewEnglandJournalofMedicine, 368, 2402-2414. https://doi.org/10.1056/nejmra1206793
[21]
Gliklich, R.E., Dreyer, N.A. and Leavy, M.B. (2014) Patient Registries. Registries for Evaluating Patient Outcomes: A User’s Guide. 3rd Edition, Agency for Healthcare Research and Quality (US).
[22]
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., et al. (2015) Intensive Supportive Care Plus Immunosuppression in IgA Nephropathy. NewEnglandJournalofMedicine, 373, 2225-2236. https://doi.org/10.1056/nejmoa1415463
[23]
Rauen, T., Wied, S., Fitzner, C., Eitner, F., Sommerer, C., Zeier, M., et al. (2020) After Ten Years of Follow-Up, No Difference between Supportive Care Plus Immunosuppression and Supportive Care Alone in IgA Nephropathy. KidneyInternational, 98, 1044-1052. https://doi.org/10.1016/j.kint.2020.04.046
[24]
Lv, J., Wong, M.G., Hladunewich, M.A., Jha, V., Hooi, L.S., Monaghan, H., et al. (2022) Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA, 327, 1888-1898. https://doi.org/10.1001/jama.2022.5368
[25]
Stamellou, E., Bruchfeld, A., Caravaca-Fontan, F., Frangou, E., Kronbichler, A., Mirioglu, S., et al. (2025) The 2025 KDIGO IgA Nephropathy Guideline Update: An ERA Immunonephrology Working Group Perspective. ClinicalKidneyJournal, 18, sfaf324. https://doi.org/10.1093/ckj/sfaf324
[26]
Wang, H., He, L., Feng, L., Zhang, W., Liu, N. and Zhang, W. (2024) Non-Invasive Assessment of IgA Nephropathy Severity with [18F]AlF-NOTA-FAPI-04 PET/CT Imaging. ClinicalKidneyJournal, 17, sfae340. https://doi.org/10.1093/ckj/sfae340
[27]
Klinkhammer, B.M., Lammers, T., Mottaghy, F.M., Kiessling, F., Floege, J. and Boor, P. (2021) Non-Invasive Molecular Imaging of Kidney Diseases. Nature Reviews Nephrology, 17, 688-703. https://doi.org/10.1038/s41581-021-00440-4
[28]
Barratt, J., Lafayette, R.A. and Floege, J. (2024) Therapy of IgA Nephropathy: Time for a Paradigm Change. FrontiersinMedicine, 11, Article ID: 1461879. https://doi.org/10.3389/fmed.2024.1461879
[29]
Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesa？, V., Trimarchi, H., et al. (2023) Efficacy and Safety of a Targeted-Release Formulation of Budesonide in Patients with Primary IgA Nephropathy (NefIgArd): 2-Year Results from a Randomised Phase 3 Trial. TheLancet, 402, 859-870. https://doi.org/10.1016/s0140-6736(23)01554-4
[30]
Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., et al. (2023) Results from Part a of the Multi-Center, Double-Blind, Randomized, Placebo-Controlled NefIgArd Trial, Which Evaluated Targeted-Release Formulation of Budesonide for the Treatment of Primary Immunoglobulin a Nephropathy. KidneyInternational, 103, 391-402. https://doi.org/10.1016/j.kint.2022.09.017
[31]
Yang, Y. and Xu, G. (2025) Opportunities and Challenges in the Treatment of IgA Nephropathy. FrontiersinPharmacology, 16, Article ID: 1559593. https://doi.org/10.3389/fphar.2025.1559593
[32]
Coppo, R. (2025) Treating IgA Nephropathy: Looking at the Future without Forgetting the Past. JournalofClinicalMedicine, 14, Article No. 4045. https://doi.org/10.3390/jcm14124045
[33]
Rovin, B.H., Barratt, J., Heerspink, H.J.L., Alpers, C.E., Bieler, S., Chae, D., et al. (2023) Efficacy and Safety of Sparsentan versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results from a Randomised, Active-Controlled, Phase 3 Trial. TheLancet, 402, 2077-2090. https://doi.org/10.1016/s0140-6736(23)02302-4
[34]
Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. NewEnglandJournalofMedicine, 383, 1436-1446. https://doi.org/10.1056/nejmoa2024816
[35]
The EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in Patients with Chronic Kidney Disease. NewEnglandJournalofMedicine, 388, 117-127. https://doi.org/10.1056/nejmoa2204233
[36]
Heerspink, H.J.L., Jardine, M., Kohan, D.E., Lafayette, R.A., Levin, A., Liew, A., et al. (2025) Atrasentan in Patients with IgA Nephropathy. NewEnglandJournalofMedicine, 392, 544-554. https://doi.org/10.1056/nejmoa2409415
[37]
Perkovic, V., Barratt, J., Rovin, B., Kashihara, N., Maes, B., Zhang, H., et al. (2025) Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. NewEnglandJournalofMedicine, 392, 531-543. https://doi.org/10.1056/nejmoa2410316
[38]
Perkovic, V., Trimarchi, H., Tesar, V., Lafayette, R., Wong, M.G., Barratt, J., et al. (2026) Sibeprenlimab in IgA Nephropathy—Interim Analysis of a Phase 3 Trial. NewEnglandJournalofMedicine, 394, 635-646. https://doi.org/10.1056/nejmoa2512133
[39]
Lafayette, R., Barbour, S.J., Brenner, R.M., Campbell, K.N., Doan, T., Eren, N., et al. (2026) A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. NewEnglandJournalofMedicine, 394, 647-657. https://doi.org/10.1056/nejmoa2510198
